The mechanism by which GSK-J4 sensitises breast cancer cells to PI3K inhibitor involves silencing the IGFBP5 gene, which confers a growth advantage upon PI3K inhibitor-resistant breast cancer cells [41]. The gene discussed is PIK3CA; the disease is breast cancer.